The MITIGATE Study will evaluate the real-world clinical effectiveness of icosapent ethyl (Vascepa®) compared to usual care in patients with established atherosclerotic cardiovascular disease. The study will evaluate whether the drug, which is used to reduce the risk of heart disease and stroke, can also prevent or reduce the risk of complications from viral respiratory illnesses in older adults with heart disease.
Division of Research
2000 Broadway
Oakland, CA 94612
(510) 891-3400
Privacy Policy | Terms and Conditions
Follow us on these external social media sites that will open in a new browser window.
© 2023 Kaiser Permanente Division of Research